Keywords
How to Cite
Abstract
Using of radiochemotherapy improves short-term and long-term results of treatment in patients with primary Hodgkin’s lymphoma (HL) comparing with treatment by chemotherapy alone. The rates of 5-year, 10-year OS and DFS are 88%, 83% and 90%, 86% in case of radiochemotherapy, versus 73%, 66% and 72%, 68% using chemotherapy alone. The 5-year and 10-year OS, DFS estimates in treatment with ABVD are 84% and 83%, 75% and 74%; BEACOPP-baseline - 83% and 82%, 82% and 81% (p<0.05). At the same time ABVD chemotherapy develops less toxicity (p<0.001). The treatment with 6 cycles of ABVD is considered as the most appropriate in primary Hodgkin’s lymphoma patients with extranodal lesions. Comparison of complications rate during chemotherapy with MOPP, ABVD, BEACOPP-baseline, BEACOPP-escalated reveals major hematologic toxicity and infectious complications rate in BEACOPP-escalated program (p<0,05). The age ≥45 years, hemoglobin <105g/l, B symptoms, fibrinogen >5g/l, involvement of 3 and more areas of lymph nodes, liver involvement, inguinal lymph nodes are defined by the multiple-factor analysis as adverse prognostic factors of patients with primary Hodgkin’s lymphoma (HL) with extranodal lesions (p<0.05). Allocation of group of high risk is proved by correlation between survival and the Prognostic Score (PS). The 5-year and 10-year DFS, OS for patients with PS-0-2 estimates are 88% and 86%, 89% and 83%, for patients with PS-3-4 - 78% and 69%, 80% and 77%, for patients with PS-5-6 - 43% and 42%, 60% and 38% respectively (p<0.001).References
Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний / Под. рук. И.В. Поддубной, В.Г Савченко. - М.: Медиа Медика, 2013. - 104 с.
Andre M.P., Reman O., Federico M. et al. Interim Analysis of the Randomized EORTC/LYSA/FIL Intergroup H10 Trial On Early PET-Scan Driven Treatment Adaptation in Stage I/II Hodgkin lymphoma // Blood. - 2012. - Vol. 120. - Abstr. 549.
Batlevi C.L., Younes A. Novel therapy for Hodgkin lymphoma // Hematology. - 2013. - P. 394-399.
Borchmann P., Diehl V., Goergen H. et al. Dacarbazine is an essential component of ABVD in the treatment of early favourable Hodgkin lymphoma: results of the second interim analysis of the GHSG HD13 trial // Haematologica. - 2010. - Vol. 95. - р. 473 (Suppl). - Abstract 1146.
Brice P. Managing relapsed and refractory Hodgkin lymphoma // British Journal of Haematology. - 2008. - Vol. 141. - P. 3-13.
Canellos G.P., Anderson J.R., Propert J.R. et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD or MOPP alternating with ABVD // N. Engl. J. Med. -1992. - Vol. 327. - P. 1478-1484.
Canellos G.P., Gollub J., Neuberg D. et al. Primary systemic treatment of advanced Hodgkin’s disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up // Ann. Oncol.-2003. - Vol. 14. - P. 268-272.
Carbone P.P., Kaplan H.S., Musshoff K. et al. Report of the Committee on Hodgkin’s Disease Staging Classification // Cancer Res. - 1971. - Vol. 31. - P. 1860-1861.
Cavalieri E., Matturro A., Annechini G. et al. Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma // Br. J. Haematol. - 2009. - Vol. 50. - P. 1803-1808.
Cerci J.J., Pracchia L.F., Linardi C.C. et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma // J. Nucl. Med. - 2010. - Vol. 51. - P. 1337-1343.
Cheson B.D., Horning S.J., Coiffier B. et al. Report of an International Workshop to standardize response criteria for Non-Hodgkin’s lymphomas. // J. Clin. Oncol. - 1999. - Vol. 17. - P. 1244-1253.
Cheson B.D., Pfistner B., Juweid M.E. et al. Revised response criteria for malignant lymphoma // J. Clin Oncol. - 2007. - Vol. 25. - P. 579-586.
Connors J.M., Klimo P., Adams G. et al. Treatment of advanced Hodgkin’s disease with chemotherapy: comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and aBvD, a report from the NCI of Canada clinical trials group // J. Clin. Oncol. - 1997. -Vol. 17. - P. 1638-1645.
De Vita V.T., Serpick A.A., Carbone P.P. Combination chemotherapy in the treatment of advanced Hodgkin‘s disease // Ann. Intern. Med. - 1970. - Vol. 73. - P. 881-895.
Diehl V., Franklin J., Pfreundschuh M. et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin‘s disease // N. Engl. J. Med. - 2003. - Vol. 348. - P. 2386-2395.
Duggan D., Petroni G., Johnson J. et al. Randomized comparison of ABVD and MOPP/ABV hybrid for treatment of advanced HodgkinCs disease: Report of an Intergroup Trial CALGB 8952 (with SWOG, ECOG, NCIC) (abstr. 43) // J. Clin. Oncol. - 2003. - Vol. 21. - P. 607-614.
Eichnauer D.A., Engert A. Is there a role for BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) in relapsed Hodgkin lymphoma? // Leuk. Lymphoma. - 2009. - Vol. 50. - P. 1733-1734.
Engert A., Diehl V., Franclin J. et al. Escaleted-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study // J. Clin. Oncol. - 2009. - Vol. 27. - P. 4548-4554.
Engert A., Franklin J., Eich H.T. et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin‘s lymphoma: final results of the GHSG HD7 trial // J. Clin. Oncol. - 2007. - Vol. 25. - P. 3495-3502.
Ferm C., Eghbali H., Meerwaldt J.H. et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease // New Eng. J. Med. - 2007. - Vol. 357. - P. 1916-1927.
Franklin J., Diehl V. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin’s disease: final analysis of the HD9 randomized trial of the GHSG // Ann. Oncol. - 2002. - Vol. 13 (suppl. 1). - P. 98-101.
Gallamini A., Patti C., Viviani S. et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses // Br. J. Haematol. - 2011. - Vol. 152. - P. 551-560.
Gisselbrecht C., Mounnier N., Andre M. et al. How to define intermediate stage in Hodgkin’s lymphoma? // Eur. J. Haematol. - 2005. - Vol. 75. (suppl. 66). - P. 111-114.
Gobbi P.G., Levis A., Chisesi T. et al. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin’s lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi // J. Clin. Oncol. - 2005. - Vol. 23. - P. 9198-9207.
Gobbi P.G., Pieresca C., Federico M. et al. MOPP/ EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin’s disease: A report from the Italian Lymphoma Study Group // J. Clin. Oncol. - 1993. - Vol. 11. - P. 712-719.
Gobbi P.G., Pieresca C., Ghirardelli M.L. et al. Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin’s disease // Blood. - 1998. - Vol. 91. - P. 2704-2712.
Hasenclever D., Diehl V. A prognostic score for advanced Hodgkin’s disease: International Prognostic Factors Project on Advanced Hodgkin’s Disease // N. Engl. J. Med. - 1998. - Vol. 339. - P. 1506-1514.
Herbst C., Rehan FA., Brillant C. et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: a systematic review // Haematologica. - 2010. - Vol. 95. - P. 494-500.
Horning S.J., Hoppe R.T., Breslin S. et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: Mature results of a prospective clinical trial. // J. Clin. Oncol. - 2002. - Vol. 20. - P. 630-637.
Klimm B., Engert A. Combined modality treatment of Hodgkin’s lymphoma // Cancer. - 2009. - Vol. 15. - P. 143-149.
Kuruvilla J. Standard therapy of advanced Hodgkin lymphoma // Hematology. - 2009. - P. 497-506.
Martinelli G., Cocorocchio E., Peccatori F. et al. ChlVPP/ABVVP a firstline hybrid combination chemotherapy for advanced Hodgkin’s lymphoma: A retrospective analysis // Br. J. Haematol. - 2004. - Vol. 125. - P. 584-589.
Mocikova H., Obrtlikova P., Vackova B. et al. Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin’s lymphoma: a retrospective study // Ann. Oncol. - 2010. - Vol. 21. - P. 1222-1227.
Raanani P., Shasha Y., Perry C. et al. Is CT scan still-necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? // Ann. Oncol. - 2005. - Vol. 17. - P. 117-122.
Raemaekers J.M.M. Treatment of stage I and II Hodgkin’s lymphoma // Haematology. - 2006. - Vol. 2. - P. 161-165.
Skoetz N., Trelle S., Rancea M. et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysis // Lancet Oncol. - 2013. -Vol. 14. - P. 943-952.
Specht L.K. Hodgkin’s disease // Prognostic Factors in Cancer. 2nd. / Eds. Gospodarowicz M.K. et al. (UICC). -NY: Wiley-Liss, 2001. - P. 673-687.
Straus D.J., Johnson J.L., LaCasce A.S. et al. Doxorubicin, vinblastine and gemcitabine (CALGB 50203) for stage I/ II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET // Blood. - 2011. - Vol. 117. - P. 5314-5320.
Trotti A., Colevas A.D., Setser A. et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment // Semin. Radiat. Oncol. - 2003. - Vol. 13. - P. 176-181.
Viviani S., Bonadonna G., Santoro A. et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin’s disease: ten-year results // J. Clin. Oncol. -1996. - Vol. 14. - P 603-609.
Viviani S., Santoro A., Ragni G. et al. Gonadal toxicity after combination chemotherapy for Hodgkin’s disease. Comparative results of MOPP vs ABVD // Eur. J. Cancer Clin. Oncol. - 1985. - Vol. 21. - P. 601-605.
Viviani S., Zinzani P.L., Rambaldi A. et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned // N. Engl. J. Med. - 2011. - Vol. 365. - P. 203-212. Поступила в редакцию 25.12.2015 г.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...